Jessica M. S. Jutzy

Jessica M. S. Jutzy

Auto-generated profile, based on publicly available information

Jessica M. S. Jutzy

Loma Linda University

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SKSalma Khan
Salma Khan
JJJessica M. S. Jutzy
Jessica M. S. Jutzy
MVMalyn May A. Valenzuela
Malyn May A. Valenzuela
DTDavid Turay
David Turay
JAJonathan R. Aspe
Jonathan R. Aspe
NWNathan Wall
Nathan Wall
Survivin is expressed in prostate cancer (PCa), and its downregulation sensitizes PCa cells to chemotherapeutic agents in vitro and in vivo. Small membrane-bound vesicles called exosomes, secreted from the endosomal membrane compartment, contain RNA and protein that they readily transport via exosome internalization into recipient cells. Recent progress has shown that tumor-derived exosomes play multiple roles in tumor growth and metastasis and may produce these functions via immune escape, tumor invasion and angiogenesis. Furthermore, exosome analysis may provide novel biomarkers to diagnose or monitor PCa treatment. Exosomes were purified from the plasma and serum from 39 PCa patients, 20 BPH patients, 8 prostate cancer recurrent and 16 healthy controls using ultracentrifugation and their quantities and qualities were quantified and visualized from both the plasma and the purified exosomes using ELISA and Western blotting, respectively. Survivin was significantly increased in the tumor-derived samples, compared to those from BPH and controls with virtually no difference in the quantity of Survivin detected in exosomes collected from newly diagnosed patients exhibiting low (six) or high (nine) Gleason scores. Exosome Survivin levels were also higher in patients that had relapsed on chemotherapy compared to controls. These studies demonstrate that Survivin exists in plasma exosomes from both normal, BPH and PCa subjects. The relative amounts of exosomal Survivin in PCa plasma was significantly higher than in those with pre-inflammatory BPH and control plasma. This differential expression of exosomal Survivin was seen with both newly diagnosed and advanced PCa subjects with high or low-grade cancers. Analysis of plasma exosomal Survivin levels may offer a convenient tool for diagnosing or monitoring PCa and may, as it is elevated in low as well as high Gleason scored samples, be used for early detection.

18 August 2010 in Apoptosis
Verified
Journal Article
Closed access
PDF file
SKSalma Khan
Salma Khan
JJJessica M. S. Jutzy
Jessica M. S. Jutzy
JAJonathan R. Aspe
Jonathan R. Aspe
DMDalmor W. McGregor
Dalmor W. McGregor
JNJonathan W. Neidigh
Jonathan W. Neidigh
NWNathan Wall
Nathan Wall

1 January 2014 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
PDF file
JAJonathan R. Aspe
Jonathan R. Aspe
COCarlos J. Diaz Osterman
Carlos J. Diaz Osterman
JJJessica M.S. Jutzy
Jessica M.S. Jutzy
SDSimone Deshields
Simone Deshields
SWSonia Whang
Sonia Whang
NWNathan Wall
Nathan Wall
Background: Current therapeutic options for advanced pancreatic cancer have been largely disappointing with modest results at best, and though adjuvant therapy remains controversial, most remain in agreement that Gemcitabine should stand as part of any combination study. The inhibitor of apoptosis (IAP) protein Survivin is a key factor in maintaining apoptosis resistance, and its dominant‐negative mutant (Survivin‐T34A) has been shown to block Survivin, inducing caspase activation and apoptosis.Methods: In this study, exosomes, collected from a melanoma cell line built to harbor a tetracycline‐regulated Survivin‐T34A, were plated on the pancreatic adenocarcinoma (MIA PaCa‐2) cell line. Evaluation of the presence of Survivin‐T34A in these exosomes followed by their ability to induce Gemcitabine‐potentiative cell killing was the objective of this work.Results: Here we show that exosomes collected in the absence of tetracycline (tet‐off) from the engineered melanoma cell do contain Survivin‐T34A and when used alone or in combination with Gemcitabine, induced a significant increase in apoptotic cell death when compared to Gemcitabine alone on a variety of pancreatic cancer cell lines.Conclusion: This exosomes/Survivin‐T34A study shows that a new delivery method for anticancer proteins within the cancer microenvironment may prove useful in targeting cancers of the pancreas.

24 February 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
YHYuzhu Hou
Yuzhu Hou
HLHua L. Liang
Hua L. Liang
XYXinshuang Yu
Xinshuang Yu
ZLZhida Liu
Zhida Liu
XCXuezhi Cao
Xuezhi Cao
RWRalph Weichselbaum
Ralph Weichselbaum
Tumor-induced CD45−Ter119+CD71+ erythroid progenitor cells, termed “Ter cells,” promote tumor progression by secreting artemin (ARTN), a neurotrophic peptide that activates REarranged during Transfection (RET) signaling. We demonstrate that both local tumor ionizing radiation (IR) and anti–programmed death ligand 1 (PD-L1) treatment decreased tumor-induced Ter cell abundance in the mouse spleen and ARTN secretion outside the irradiation field in an interferon- and CD8+ T cell–dependent manner. Recombinant erythropoietin promoted resistance to radiotherapy or anti–PD-L1 therapies by restoring Ter cell numbers and serum ARTN concentration. Blockade of ARTN or potential ARTN signaling partners, or depletion of Ter cells augmented the antitumor effects of both IR and anti–PD-L1 therapies in mice. Analysis of samples from patients who received radioimmunotherapy demonstrated that IR-mediated reduction of Ter cells, ARTN, and GFRα3, an ARTN signaling partner, were each associated with tumor regression. Patients with melanoma who received immunotherapy exhibited favorable outcomes associated with decreased expression of GFRα3. These findings demonstrate an out-of-field, or “abscopal,” effect mediated by adaptive immunity, which is induced during local tumor irradiation. This effect, in turn, governs the therapeutic effects of radiation and immunotherapy. Therefore, our results identify multiple targets to potentially improve outcomes after radiotherapy and immunotherapy.

16 May 2018 in International Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
JJJessica M. S. Jutzy
Jessica M. S. Jutzy
JLJeffrey M. Lemons
Jeffrey M. Lemons
JLJason J. Luke
Jason J. Luke
SCSteven J. Chmura
Steven J. Chmura
Radiation therapy is a mainstay of treatment in early and locally advanced breast cancer but is typically reserved for palliation of symptomatic lesions in patients with metastatic breast cancer. With new advances in the field of tumor biology and immunology, the role of radiation in the metastatic setting is evolving to harness its immune-enhancing properties. Through the release of tumor antigens, tumor DNA, and cytokines into the tumor microenvironment, radiation augments the antitumoral immune response to affect both the targeted lesion and distant sites of metastatic disease. The use of immunotherapeutics to promote antitumoral immunity has resulted in improved treatment responses in patients with metastatic disease and the combination of radiation therapy and immunotherapy has become an area of intense investigation. In this article, we will review the emerging role of radiation in the treatment of metastatic disease and discuss the current state of the science and clinical trials investigating the combination of radiation and immunotherapy.

1 April 2011 in Immunobiology
Verified
Journal Article
Closed access
OOOludare Odumosu
Oludare Odumosu
KPKimberly Payne
Kimberly Payne
IBIneavely Baez
Ineavely Baez
JJJessica Jutzy
Jessica Jutzy
NWNathan Wall
Nathan Wall
WLWilliam Langridge
William Langridge